SAGE News and Press, Sage Therapeutics Inc. From 03/15/22

Data Presented at the AD/PD 2022 Advances in Science & Therapy International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders The PARADIGM Study is a Phase 2, open-label study evaluating the safety, tolerability, and effic...

Biogen stock is near a multi-year low. The pipeline of potential new drugs is deep. When new drug revenue might surpass old drug declines is difficult to foresee. For further details see: Biogen: Beyond The Doom And Gloom

The following slide deck was published by Sage Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Sage Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Cowen 42 ...

Sage Therapeutics, Inc. (SAGE) Q4 2021 Earnings Conference Call February 24, 2022, 8:00 am ET Company Participants Helen Rubinstein - Director, IR Barry Greene - CEO Jim Doherty - CDO Kimi Iguchi - CFO Chris Benecchi - CCO Conference Call Participants Andrea Tan - Goldman Sachs Tiffany Sun - ...

Sage Therapeutics press release (NASDAQ:SAGE): Q4 GAAP EPS of -$2.12 beats by $0.05. Revenue of $1.6M (-99.9% Y/Y) misses by $0.17M. Ended 2021 with cash balance of $1.7 billion; anticipate ending 2022 with a cash balance of approximately $1.3 billion. The Company does not anticipate receipt ...

Rolling NDA submission for zuranolone in MDD expected to begin in early 2022 and planned to be completed in the second half of 2022 now supported by data from six positive clinical studies An associated NDA submission in PPD expected in 2023; Fast Track designation received ...

Sage Therapeutics (NASDAQ:SAGE) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$2.16 and the consensus Revenue Estimate is $1.77M (-99.8% Y/Y). Over the last 1 year, SAGE has beaten EPS estimates 50% of the time...

Sage Therapeutics (NASDAQ: SAGE) is having a tough time today. After releasing the long-awaited phase 3 trial results for its rapid-onset drug zuranolone as a treatment for major depressive disorder (MDD) this morning, the drugmaker's shares immediately hit the skids. Sage's sto...

Gainers: HOOKIPA Pharma (NASDAQ:HOOK) +46%. Kinnate Biopharma (NASDAQ:KNTE) +9%. Corcept Therapeutics (NASDAQ:CORT) +7%. Alkermes (NASDAQ:ALKS) +5%. Celularity (NASDAQ:CELU) +3%. Losers: Masimo (NASDAQ:MASI) -36%. Baudax Bio (NASDAQ:BXRX) -20%. ...